Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats

Urological Research

Volumn 32, Issue 4, 2004, Pages 278-282

  Parlakpinar, H ^a   Koc, M ^a   Polat, A ^a   Vardi, N ^a   Ozer, M K ^a   Turkoz, Y ^a   Acet, A ^a  

^a INONU UNIVERSITY   (Turkey)

Author keywords

Amikacin; Aminoguanidine; Malondialdehyde; Rat; Renal injury

Indexed keywords

AMIKACIN; AMIKOZIT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGUANIDINE; ANTIOXIDANT; CREATININE; GLUTATHIONE; MALONALDEHYDE; NITROGEN; REACTIVE OXYGEN METABOLITE; SCAVENGER; SERUM ALBUMIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; UREA;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; GLOMERULAR STRUCTURE; HISTOPATHOLOGY; KIDNEY TUBULE DAMAGE; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; RAT; RENAL PROTECTION; TISSUE LEVEL; TISSUE STRUCTURE; UREA NITROGEN BLOOD LEVEL;

AMIKACIN; ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FEMALE; GUANIDINES; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIPID PEROXIDATION; MALONDIALDEHYDE; PROBABILITY; PROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY;

EID: 4544383616     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00240-004-0399-5     Document Type: Article

References (31)

1. Begg EJ, Barclay ML (1995) Aminoglycosides-50 years on. Br J Clin Pharmacol 39: 597
2. Klein J, Koren G, McLeod SM (1992) Comparison methods for prediction of nephrotoxicity during development. Dev Pharmacol Ther 19: 80
3. Ibrahim S, Langhendries JP, Bernard A, Tulkens PM (1994) Urinary phospholipids excretion in neonates treated with amikacin. Int J Clin Pharmacol Res 14: 149
4. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV (1998) In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53: 394
5. Rao M, Kumar MM, Rao MA (1999) In vitro and in vivo effects of phenolic antioxidants against cisplatin-induced nephrotoxicity. J Biochem 125: 383
6. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, Currie MG (1993) Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 233: 119
7. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML (1993) Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation endproduct formation. Diabetes 42: 221
8. Sugimoto K, Yagihashi S (1997) Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. Microvasc Res 53: 105
9. Ihm SH, Yoo HJ, Park SW, Ihm J (1999) Effect of aminoguanidine on lipid peroxidation in streptozotocin induced diabetic rats. Metabolism 48: 1141
10. Szabo C, Ferrer-Sueta G, Zingarelli B, Southan GJ, Salzman AL, Radi R (1997) Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J Biol Chem 272: 9030
11. Aoki K, Ohmori M, Takimoto M, Ota H, Yoshida T (1997) Cocaine-induced liver injury in mice is mediated by nitric oxide and reactive oxygen species. Eur J Pharmacol 336: 43
12. Shiomi M, Wakabayashi Y, Sano T, Sinoda Y, Nimura Y, Ishimura Y, Suematsu M (1998) Nitric oxide suppression reversibly attenuates mitochondrial dysfunction and cholestasis in endotoxemic rat liver. Hepatology 27: 108
13. Al-Shabanah OA, Alam KS, Nagi MN, Al-Rikabi AC, Al-Bekairi AM (2000) Protective effect of aminoguanidine, a nitric oxide synthase inhibitor, against carbon tetrachloride induced hepatotoxicity in mice. Life Sci 66: 265
14. Mansour MA, Mostafa AM, Nagi MN, Khattab MM, Al-Shabnah OA (2002) Protective effect of aminoguanidine against nephrotoxicity induced by cisplatin in normal rats. Comp Biochem Physiol C 132: 123
15. Parlakpinar H, Ozer MK, Sahna E, Vardi N, Cigremis Y, Acet A (2003) Amikacin-induced acute renal injury in rats protective role of melatonin. J Pineal Res 35: 85
16. Takizawa S, Fukuyama N, Hirabayashi H, Nakazawa H, Shinohara Y (1999) Dynamics of nitrotyrosine formation and decay in rat brain during focal ischemia-reperfusion J Cereb Blood Flow Metab 19: 667
17. Vermeulen NPE, Baldew GS (1992) The role of lipid peroxidation in the nephrotoxicity of cisplatin. Biochem Pharmacol 44: 1193
18. Sahna E, Parlakpinar H, Ozturk F, Cigremis Y, Acet A (2003) The protective effects of physiological and pharmacological concentrations of melatonin on renal ischemia-reperfusion injury in rats. Urol Res 31: 188
19. Walker RJ, Duggin GG (1988) Drug nephrotoxicity. Annu Rev Pharmacol Toxicol 28: 331
20. Moore RD, Lietman PS, Smith C (1987). Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155: 93
21. Prins JM, Weverling GJ, De Blok K, Van Ketel RJ, Speelman P (1996) Validation and nephrotoxicity of a simplified once-daily aminoglycoside schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 40: 2494
22. Smith CR, Lipsky JJ, Laskin OL, Hellman DB, Mellits ED, Longstreth J, Lietman PS (1980) Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 302: 1106
23. Gilbert DN (1995) Aminoglycosides. Principles and practice of infectious diseases, 4th edn. Churchill Livingstone, New York, p 279
24. Hagiwara M, Inagaki M, Kanamura K, Ohta H, Hidaka H (1988) Inhibitory effects of aminoglycosides on renal protein phosphorylation by protein kinase C. J Pharmacol Exp Ther 244: 355
25. Halliwell B, Gutteridge JMC, Cross CE (1992) Free radicals, antioxidants and human disease. Where are we now? J Lab Clin Med 119: 598
26. Wolff SP (1993) Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stressing the etiology of diabetes mellitus and complications. Br Med Bull 49: 642
27. Yildiz G, Demiryurek AT, Sahin-Erdemli I, Kanzik I (1998) Comparison of antioxidant activities of aminoguanidine, methyl-guanidine and guanidine by luminol-enhanced chemiluminescence. Br J Pharmacol 124: 905
28. Giardino I, Fard AK, Hatchell DL, Brownlee M (1998) Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 47:1114
29. Babu E, Gopalakrishnan VK, Sriganth IN, Gopalakrishnan R, Sakthisekaran D (1995) Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 144: 7
30. Parlakpinar H, Sahna E, Ozer MK, Ozugurlu F, Vardi N, Acet A (2002) Physiological and pharmacological concentrations of melatonin protect against cisplatin induced acute renal injury. J Pineal Res 33: 161
31. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H (1999) Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumor necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42: 878